Citations

Clear

4610 citation(s) found for "Lu, Brian".

Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology
Gordon, Brian A. , Dincer, Aylin , Keefe, Sarah , Hobbs, Diana A. , Hornbeck, Russ C. , Franklin, Erin , Dyck, Christopher H. van , Klein, Gregory , Pariente, Jérémie , Bateman, Randall J. , Morris, John C. , Perrin, Richard J. , Gordon, Brian A , Bateman, Randall J , Morris, John C , Flores, Shaney , McKay, Nicole S. , Wisch, Julie K. , Jack, Clifford R. , Koeppe, Robert A. , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S1 | Pages: No page available

10.1002/alz.063285 Get It

AbstractBackgroundTau PET imaging is an established tool for studying Alzheimer Disease but its sensitivity to primary age‐related tauopathy (PART) as well as sex effects in individuals without abnormal levels of amyloid are unknown.MethodsCross‐sectional data were collected from 2014 to 2019 in 144 cognitively normal younger, middle‐aged, and older adults free from amyloid pathology as quantified using PET. Regional values of tau PET binding were measured using flortaucipir. Statistical models examined the main effects of increasing age, sex, race, and subthreshold levels of amyloid. Secondary analyses also examined the relationship between tau PET binding and iron as measured using T2* weighted imaging and calcification as measured using CT.ResultsThere were significant positive associations between tau binding and age in 19 regions, with the largest effects seen in the inferior temporal cortex (t=4.59), caudate (t=9.58), and putamen (t=12.57). Iron as measured using T2* imaging mediated only a modest (11.9%) amount of the association between age and tau binding. Elevated tracer uptake in females was present in 23 regions in frontal, lateral parietal, and temporal regions including, most prominently the rostral middle frontal gyrus (t=7.48), superior temporal gyrus (t=5.12) and the inferior temporal gyrus (t=4.22). There were no significant effects of race or subthreshold levels of amyloid.ConclusionsTau PET is sensitive to primary effects of age in regions consistent with the neuropathological definition of PART although strong age effects in regions of off‐target binding were also present. There was a robust effect of sex, suggesting prior observations of elevated binding in women is not solely a potentiation of Alzheimer pathology but instead represents an ubiquitous phenomenon. Understand how both sex and age impact tracer binding is critical to understanding the utility of PET tracers as well as interpreting tracer values in the context of disease.
Paging the Clinical Informatics Community: Respond STAT to Dobbs v. Jackson's Women's Health Organization
Ravi, Akshay , Weia, Benjamin , Aarts, Jos , Ahmad, Hasan B., Araj, Ellen, Bauml, Julie A., Boyd, Andrew D. , Brecht-Doscher, Aimee, Butler‐Henderson, Kerryn , Butte, Atul J. , Cardilo, Anthony B., Chilukuri, Nymisha , Cho, Mildred K. , Cohen, Jenny K., Craven, Catherine K. , Crusco, Salvatore, Dadabhoy, Farah Z. , Dash, Dev , DeBolt, Claire , Fayanju, Oluseyi A, Fochtmann, Laura J. , Graham, Justin V., Hanna, John , Hofford, Mackenzie , Hron, Jonathan D. , Huang, Sean S, Jackson, Brian R. , Kaplan, Bonnie , Kelly, William R. , Ko, Kyungmin, Kurapati, Nikhil , Labbad, Gabriel , Lee, Julie , Leitner, Stefano, Liao, Zachary C , Melnick, Edward R. , Muniyappa, Anoop , Murray, Sara G. , Nichols-Johnson, Victoria, Novak, Laurie L. , Ogan, William Scott , Ozeran, Larry, Pageler, Natalie M. , Pandita, Deepti , Perumbeti, Ajay, Petersen, Carolyn , Pierce, Logan , Puttagunta, Raghuveer, Ramaswamy, Priya , Rogers, Kendall, Ryan, Angela M., Sarabu, Chethan , Shaw, Kate A. , Spector, Jacob D. , Starren, Justin , Stoffel, Michelle , Swanson, Karl , Tomes, Adrian, Unertl, Kim M. , Weon, Jenny L. , Wiley, Kevin , Winkelstein, Peter , Wong, Jenson, Xie, James , Yarahuan, Julia , Yung, Nathan , Zera, Chloe , Sadasivaiah, Shobha , Boyd, Andrew D , Melnick, Edward R , Petersen, Carolyn , Arvisais‐Anhalt, Simone , Benham‐Hutchins, Marge , Brecht-Doscher, Aimee, Elkin, Peter L. , Hersh, William , Kelly, William, Koppel, Ross , Lehmann, Christoph U. , Medford, Richard J , Neinstein, Aaron Barak , Rosenbloom, S. Trent , Ryan, Angela, Saleh, Sameh Nagui , Schreiber, Richard , Sim, Ida , Sirintrapun, Sahussapont Joseph , Solomonides, Anthony , Subbian, Vignesh , Trang, Karen , Whooley, Mary A. , Williamson, Drew F. K. , Ratanawongsa, Neda

Mayo Clinic

Applied Clinical Informatics | December 19, 2022 | Volume: 14 | Issue: 01 | Pages: 164-171

10.1055/a-2000-7590 | PMID 36535703 Get It

Effects of Image Quality on the Accuracy Human Pose Estimation and Detection of Eye Lid Opening/Closing Using Openpose and DLib
Ye, Run Zhou , Subramanian, Arun , Diedrich, Daniel A. , Lindroth, Heidi , Pickering, Brian W. , Herasevich, Vitaly , Diedrich, Daniel, Lindroth, Heidi , Herasevich, Vitaly , Ye, Run Zhou

Mayo Clinic

Journal of Imaging | December 19, 2022 | Volume: 8 | Issue: 12 | Pages: 330

10.3390/jimaging8120330 | PMID 36547495 Get It

Objective: The application of computer models in continuous patient activity monitoring using video cameras is complicated by the capture of images of varying qualities due to poor lighting conditions and lower image resolutions. Insufficient literature has assessed the effects of image resolution, color depth, noise level, and low light on the inference of eye opening and closing and body landmarks from digital images. Method: This study systematically assessed the effects of varying image resolutions (from 100 × 100 pixels to 20 × 20 pixels at an interval of 10 pixels), lighting conditions (from 42 to 2 lux with an interval of 2 lux), color-depths (from 16.7 M colors to 8 M, 1 M, 512 K, 216 K, 64 K, 8 K, 1 K, 729, 512, 343, 216, 125, 64, 27, and 8 colors), and noise levels on the accuracy and model performance in eye dimension estimation and body keypoint localization using the Dlib library and OpenPose with images from the Closed Eyes in the Wild and the COCO datasets, as well as photographs of the face captured at different light intensities. Results: The model accuracy and rate of model failure remained acceptable at an image resolution of 60 × 60 pixels, a color depth of 343 colors, a light intensity of 14 lux, and a Gaussian noise level of 4% (i.e., 4% of pixels replaced by Gaussian noise). Conclusions: The Dlib and OpenPose models failed to detect eye dimensions and body keypoints only at low image resolutions, lighting conditions, and color depths. Clinical Impact: Our established baseline threshold values will be useful for future work in the application of computer vision in continuous patient monitoring.
1848. Predictors of 6-Month Mortality in Staphylococcus aureus Bacteremia: A Population-Based Study in Olmsted County, Minnesota, from 2006 to 2020
Lahr, Brian D. , Hindy, Joya-Rita , Quintero-Martinez, Juan Andres , DeSimone, Daniel C. , Baddour, Larry M.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1477 Get It

Abstract Background Staphylococcus aureus has high mortality rates, which is influenced by several factors related to the host-pathogen interaction. The current study aims to provide a contemporary evaluation of predictors of 6-month mortality rate in a population-based cohort of incident Staphylococcus aureus bacteremia (SAB) cases. Methods Retrospective population-based study of 541 adult residents of Olmsted County, MN with monomicrobial SAB from January 1, 2006 through December 31, 2020. The study’s primary outcome was 6-month mortality rate, and a survival analysis was prepared by the Kaplan-Meier method. Multivariable Cox regression was used to investigate risk factors associated with 6-month mortality. Results The median (IQR) age of 541 patients with SAB was 66.8 (54.4-78.5) years and 39.6% were female. The median Charlson Comorbidity Index (CCI) was 2 (1-4). SAB cases were healthcare-associated in 49.2% and 56.2% were methicillin-susceptible. Twenty percent of SAB cases had an unknown infection source and 38.3% had complicated bacteremia. There were 7 relapses within the first 12 weeks of follow-up, corresponding to a cumulative incidence rate of 1.3%. There were no re-infections through the remainder of the 6-month follow-up, although there were 2 recurrences after 7 months. Eighty-nine (16.5%) patients died within 1 month of SAB diagnosis and 144 (26.7%) patients died during the 6-month follow-up period. In a multivariable analysis, older age, elevated CCI, unknown source of SAB, and intensive care unit (ICU) admission were significant predictors of an increased 6-month mortality rate. In contrast, presence of diabetes mellitus was significantly associated with a decreased 6-month mortality rate; also, undergoing infectious diseases consultation was associated with reduced mortality in the first 2 weeks, but not for the remainder of the 6-month follow-up period. Conclusion To our knowledge, the current investigation represents the only contemporary population-based study determining significant predictors of mortality in SAB patients, namely, older age, higher CCI, unknown source of SAB, and ICU admission. This study also described one of the lowest 30-day mortality rates reported over the past 2 decades. Figure 1.Survival and reinfection rates of patients with SAB over 6 months. Abbreviations: SAB, Staphylococcus aureus bacteremia. Foot notes: The overall survival curve was derived by the Kaplan-Meier estimator, while the curve for reinfection was estimated by the cumulative incidence function taking into account the competing risk of death. Disclosures Larry M. Baddour, M.D., Boston Scientific: Advisor/Consultant|Botanix Pharmaceuticals: Advisor/Consultant|Roivant Sciences: Advisor/Consultant|UpToDate, Inc.: Royalty payments - authorship duties.
990. Sex-Specific Analysis of Clinical Features and Outcomes in Staphylococcal Periprosthetic Joint Infections Managed with Two-Stage Exchange Arthroplasty
Higgins, Eibhlin, Lahr, Brian D. , Higgins, Eibhlin , Tai, Don Bambino Geno , Suh, Gina A. , Tande, Aaron J.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.832 Get It

Abstract Background There are anatomical, pharmacokinetic, and joint biomechanical differences between males and females. Whether these differences result in differing presentation, treatment tolerability and outcomes in periprosthetic joint infection (PJI) has not been widely evaluated. Methods We undertook a retrospective case matched study of patients with staphylococcal PJI managed with two-stage exchange arthroplasty. In order to control for differences other than sex which may influence outcome or presentation, males and females were case-matched for age, causative organism (Coagulase-negative staphylococci vs Staphylococcus aureus) and joint involved. The two matched groups were analyzed for differences in duration of symptoms, inflammatory markers, duration of hospital stay, antimicrobial side effects, post-operative complications and recurrence rate. Recurrence of infection was defined as per Musculoskeletal Infection Society criteria for PJI and included both relapse with original microorganism or with an additional organism. Results 78 pairs of males and females with staphylococcal PJI were successfully matched. There were no significant baseline differences by sex, except for greater use of chronic immunosuppression among females (16.7% vs. 4.1%; p=0.012). Clinical characteristics and outcomes of the patients are summarized in table 1. We did not detect a statistically significant between the outcomes of the two groups. Overall, 16 recurrent infections occurred during a median follow-up time of 2.9 (IQR: 1.5 - 5.3) years. The 3-year cumulative incidence of treatment failure depicted in figure 1 was 16.1% for females, compared with 8.8% for males (p=0.434). Conclusion Success rates for PJI treated with two-stage exchange arthroplasty are high consistent with previously reported literature. A larger cohort of patients may be required to detect differences in relapse rates. This study included only staphylococcal PJI and was thus unable to evaluate the differences in microbiology of PJI between males and females, which could also impact outcomes. This retrospective case-matched study did not detect any significant differences in outcomes between males and females with staphylococcal PJI who underwent two stage exchange arthroplasty. Disclosures Gina A. Suh, M.D., Adaptive Phage Therapeutics (APT): Grant/Research Support|Adaptive Phage Therapeutics (APT): Dr. Suh received grants and has an equity and royalty-bearing know-how agreement with Adaptive Phage Therapeutics but is unrelated to project Aaron J. Tande, M.D., Uptodate: Dr Tande has received an honorarium from Uptodate for medical writing unrelated to this project.
1816. Bloodstream Infection Following Arterial Aneurysm Repair: A Population-Based Study
Tabaja, Hussam , Chesdachai, Supavit , Lahr, Brian D. , Chesdachai, Supavit , Tabaja, Hussam , Baddour, Larry M. , DeMartino, Randall R. , DeSimone, Daniel C.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.1446 Get It

Abstract Background Bloodstream infection (BSI) following arterial aneurysm repair may signify vascular graft infection (VGI). The incidence of BSI and its implications in patients with arterial grafts have received scant attention with limited contemporary study. Therefore, the aim of the current investigation is to describe the incidence and epidemiology of BSI following arterial aneurysm repair in a population-based cohort. Methods Retrospective case-cohort study using the expanded Rochester Epidemiology Project (e-REP) to identify all arterial aneurysm repairs performed in adults (>18 years) residing in eight counties in southern Minnesota between January 1, 2010 and December 31, 2020. All repairs were performed at Mayo Clinic Rochester. Electronic health records were screened for initial BSI episode following aneurysm repair and complicating VGI. Results Overall, 643 patients underwent 708 aneurysm repairs: 417 endovascular and 291 open surgical repairs. Forty-two patients developed BSI during 2,992 cumulative person-years of follow-up. The median time from repair to BSI was 3.1 [interquartile range 0.5, 6.4] years. The BSI incidence rate, in cases per 1000 person-years, was 14.0 (95% CI 10.1-19.0) overall, including 18.2 (95% CI 11.9-26.7) following open surgical repair and 10.2 (95% CI 5.8-16.6) following endovascular repair (p=0.148). Thirty-nine (92.9%) of the BSI cases were monomicrobial, with 18 (46.2%) due to Gram-positive organisms and 21 (53.8%) due to Gram-negative organisms. Of the 42 patients with BSI, 10 (23.8%) had VGI. VGI occurred in 8/18 (44.4%) monomicrobial Gram-positive BSI as compared to 2/21 (9.5%) monomicrobial Gram-negative BSI (p=0.013). The 3-year mortality rate following BSI was 52.3%. Conclusion There was no statistically significant difference in incidence rates of BSI following open surgical repair and endovascular repair. Higher rates of VGI were seen with Gram-positive BSI as compared to Gram-negative BSI. Disclosures Larry M. Baddour, M.D., Boston Scientific: Advisor/Consultant|Botanix Pharmaceuticals: Advisor/Consultant|Roivant Sciences: Advisor/Consultant|UpToDate, Inc.: Royalty payments - authorship duties.
1036: DIGITAL HEALTH STRATEGIES TO SUPPORT CLINICIAN ICU POPULATION MANAGEMENT: A CROSSOVER STUDY
Lipatov, Kirill , Pinevich, Yuliya , Pickering, Brian, Herasevich, Svetlana , Barwise, Amelia , Lindroth, Heidi , Dong, Yue , Herasevich, Vitaly , Pickering, Brian

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 512-512

10.1097/01.ccm.0000909872.67739.e4 Get It

1032: CRITICAL CARE CLINICIAN NEEDS FOR PRIORITIZATION OF CARE IN INTENSIVE CARE UNIT: A QUALITATIVE STUDY
Pinevich, Yuliya , Pickering, Brian, Herasevich, Svetlana , Lindroth, Heidi , Herasevich, Vitaly , Pickering, Brian, Barwise, Amelia

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 510-510

10.1097/01.ccm.0000909856.52081.a2 Get It

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Tempero, Margaret A. , Pelzer, Uwe , Oh, Do‐Youn , Li, Chung‐Pin , Tortora, Giampaolo , Chang, Heung-Moon, Lopez, Charles D. , Bekaii‐Saab, Tanios , Ko, Andrew H. , Santoro, Armando , Noel, Marcus Smith , Dean, Andrew , Riess, Hanno, Philip, Philip, Moore, Malcolm J. , Goldstein, David , Ferrara, Stefano, Bruchec, Yvan Le, Lu, Brian , Epstein, Richard A. , Vasey, Paul L., Shapiro, Jeremy, Burge, Matthew , Chua, Yu Jo , Harris, Marion , Prager, Gerald W. , Dittrich, Christian , Längle, Friedrich, Philipp‐Abbrederis, Kathrin, Greil, Richard , Stöger, Herbert, Girschikofsky, Michael , Kuehr, Thomas, Laethem, Jean–Luc Van, Laurent, Stéphanie , Ko, Yoo Joung, Dowden, Scot, Kavan, Petr , Tehfe, Mustapha Édouard, Kubala, Eugen, Kohoutek, Milan, Yilmaz, Mette, Parner, Vibeke K., Salminen, Tapio , Soveri, Leena‐Maija , Korkeila, Eija, Taı̈eb, Julien , Artru, Pascal , Guimbaud, Rosine , Turpin, Antony, Kunzmann, Volker , Kreth, Florian, Oettle, Helmut, Karthaus, Meinolf , Folprecht, Gunnar , Kullmann, Frank , Reiser, Marcel , Heinemann, Volker , Wörns, Marcus‐Alexander , Schulz, H. , Garlipp, Benjamin , Chan, Lam Stephen, Juhász, Balázs , Landherr, László, Pintér, Tamás , Kahán, Zsuzsanna , McDermott, Raymond, Power, Derek G. , Siena, Salvatore, Milella, Michèle , Bagalá, Cinzia, Roila, Fausto, Fanello, Silvia, Wilmink, Johanna W. , Groot, Jan Willem de, Creemers, G.J., Rodrigues, Tânia , Tai, David , Mercadé, T. Macarulla, Medina, Manuel Hidalgo, Mena, Alfredo Carrato, Santasusana, Joan Maurel, Oncala, Maria Jose Flor, Martín, Carlos Gómez , Muñoz, Andrés, García, Ruth Vera, Alés, Inmaculada, Rivera, Fernando , Sastre, Javier , Wu, Cheng‐Chung, Tien, Yu‐Wen , Chan, De-Chuan , Hwang, Tsann‐Long , Evans, Jeffry, Wadsley, Jonathan , Chiorean, E. Gabriela , Bendell, Johanna C. , Kindler, Hedy L. , Fernando, Nishan H., Beg, Muhammad Shaalan , LoConte, Noelle K. , Posey, James , Malhotra, Rajat, Sohal, Davendra , Brenner, Warren, Womack, Mark, Seth, Rahul , lyer, Renuka, Bahary, Nathan , Marsh, Robert , Chua, Cynthia C., Reeves, J. N. , Manji, Gulam A. , Sahai, Vaibhav , Messersmith, Wells A. , Zakari, Ahmed, Bullock, Andrea J. , Musher, Benjamin , Kim, Edward , Bajor, David J., Huyck, Tim, Hatoum, Hassan , Xiong, Henry, Pasche, Boris , Lacy, Jill , Olowokure, Olugbenga, Cohn, Allen Lee, Richards, Donald , Martin, Robert C.G. , Paulson, Andrew Scott , Fanta, Paul T. , Krishnamurthi, Smitha , Fuloria, Jyotsna, McDermott, Ray , Turpin, Anthony , O'Reilly, Eileen M , Winter, Jordan Michael , Oh, Do-Youn , Li, Chung-Pin , Tortora, Giampaolo , Bekaii-Saab, Tanios S , Santoro, Armando , Park, Joon Oh , Dean, Andrew , Van Cutsem, Eric , Berlin, Jordan D. , Tabernero, Josep , Biankin, Andrew V , LoConte, Noelle , Taieb, Julien , McDermott, Ray , Prager, Gerald W , Sahai, Vaibhav , O’Reilly, Eileen M. , Frassineti, Giovanni Luca , Shan, Yan‐Shen , Cutsem, Eric Van , Tabernero, Josep , Li, Mingyu , Zhang, George , Biankin, Andrew V. , Reni, Michele , Vasey, Paul, Pavlakis, Nick , Tebbutt, Niall C. , Längle, Friedrich, Dhani, Neesha C. , Tehfe, Mustapha , Pfeiffer, Per , Osterlund, Pia J. , Tougeron, David , Caroli‐Bosc, François‐Xavier , Walter, Thomas , Bachet, Jean‐Baptiste , Block, Andreas, Venerito, Marino , Trojan, Jörg , Lerch, Markus M. , Schulz, Holger, Yau, Thomas , Juhasz, Balazs, Bodoky, Gyorgy , Gianni, Luca , Siena, Salvatore , Falcone, Alfredo , Berardi, Rossana , Costanzo, Francesco Di , Ardizzoni, Andrea , Maiello, Evaristo , Barroso, Eduardo , Sarmento, Cristina, Chee, Cheng Ean , López López, Rafael , Sáez, Berta Laquente, Chan, De‐Chuan , Evans, Jeffry, Corrie, Pippa G. , Cardin, Dana B. , Noonan, Anne M. , George, Thomas J. , Arena, Francis P. , McWilliams, Robert R. , Seth, Rahul, Ramirez, Robert A. , Reeves, James, El-Khoueiry, Anthony B. , Weaver, Robert, Dreicer, Robert , Borad, Mitesh J. , Huyck, Timothy K., Xiong, Henry Q., Oberstein, Paul E.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2022 | Volume: 41 | Issue: 11 | Pages: 2007-2019

10.1200/jco.22.01134 | PMID 36521097 Get It

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assigned 866 treatment-naive patients with pancreatic ductal adenocarcinoma to nab-paclitaxel (125 mg/m 2 ) + gemcitabine (1,000 mg/m 2 ) or gemcitabine alone to one 30-40 infusion on days 1, 8, and 15 of six 28-day cycles. The primary end point was independently assessed disease-free survival (DFS). Additional end points included investigator-assessed DFS, overall survival (OS), and safety. RESULTS Two hundred eighty-seven of 432 patients and 310 of 434 patients completed nab-paclitaxel + gemcitabine and gemcitabine treatment, respectively. At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 ( nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P = .18). The median investigator-assessed DFS was 16.6 (IQR, 8.4-47.0) and 13.7 (IQR, 8.3-44.1) months, respectively (HR, 0.82; 95% CI, 0.694 to 0.965; P = .02). The median OS (427 events; 68% mature) was 40.5 (IQR, 20.7 to not reached) and 36.2 (IQR, 17.7-53.3) months, respectively (HR, 0.82; 95% CI, 0.680 to 0.996; P = .045). At a 16-month follow-up (cutoff, April 3, 2020; median follow-up, 51.4 months [IQR, 47.0-57.0]), the median OS (511 events; 81% mature) was 41.8 ( nab-paclitaxel + gemcitabine) versus 37.7 months (gemcitabine; HR, 0.82; 95% CI, 0.687 to 0.973; P = .0232). At the 5-year follow-up (cutoff, April 9, 2021; median follow-up, 63.2 months [IQR, 60.1-68.7]), the median OS (555 events; 88% mature) was 41.8 versus 37.7 months, respectively (HR, 0.80; 95% CI, 0.678 to 0.947; P = .0091). Eighty-six percent ( nab-paclitaxel + gemcitabine) and 68% (gemcitabine) of patients experienced grade ≥ 3 treatment-emergent adverse events. Two patients per study arm died of treatment-emergent adverse events. CONCLUSION The primary end point (independently assessed DFS) was not met despite favorable OS seen with nab-paclitaxel + gemcitabine.
236: OBSERVATIONAL COHORT STUDY OF MAYO CLINIC VIRUS REGISTRY COVID-19 INPATIENTS
Malinchoc, Michael, Garces, Juan Pablo Domecq , Pickering, Brian W. , Barwise, Amelia , Tekin, Aysun , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 103-103

10.1097/01.ccm.0000906680.39709.fd Get It